Salivary IgA enhancement strategy for development of a nasal-spray anti-caries mucosal vaccine

Science China Life Sciences

Volumn 56, Issue 5, 2013, Pages 406-413

  Yan, HuiMin ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

Author keywords

caries vaccine; mucosal immunization; mutans streptococci; PAc; secretory IgA

Indexed keywords

STREPTOCOCCUS; STREPTOCOCCUS MUTANS;

EID: 84876969765     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-013-4473-5     Document Type: Review

References (71)

1. Hajishengallis G, Russell M W, Michalek S M. Comparison of an adherence domain and a structural region of Streptococcus mutans antigen I/II in protective immunity against dental caries in rats after intranasal immunization. Infect Immun, 1998, 66: 1740-1743.
2. Hamada S, Slade H D. Biology, immunology, and cariogenicity of Streptococcus mutans. Microbiol Rev, 1980, 44: 331-384.
3. Loesche W J. Role of Streptococcus mutans in human dental decay. Microbiol Rev, 1986, 50: 353-380.
4. Saekel R. Oral health data from China and their relevance for Germany. Prophylaxe Impuls, 2010, 14: 6.
5. Shang X H, Li D L, Huang Y, et al. Prevalence of dental caries among preschool children in Shanghe County of Shandong Province and relevant prevention and treatment strategies. Chin Med J (Engl), 2008, 121: 2246-2249.
6. Qi X Q. Report of the Third National Oral Health Survey. Beijing: People's Medical Publishing House, 2008.
7. Fan M W, Bian Z, Peng Z X, et al. A DNA vaccine encoding a cell-surface protein antigen of Streptococcus mutans protects gnotobiotic rats from caries. J Dent Res, 2002, 81: 784-787.
8. Jia R, Guo J H, Fan M W, et al. Immunogenicity of CTLA4 fusion anti-caries DNA vaccine in rabbits and monkeys. Vaccine, 2006, 24: 5192-5200.
9. Lewis D J, Huo Z, Barnett S, et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE, 2009, 4: e6999.
10. Liang S, Hosur K B, Nawar H F, et al. In vivo and in vitro adjuvant activities of the B subunit of Type IIb heat-labile enterotoxin (LT-IIb-B5) from Escherichia coli. Vaccine, 2009, 27: 4302-4308.
11. Smith D J. Prospects in caries vaccine development. J Dent Res, 2012, 91: 225-226.
12. Xu Q A, Yu F, Fan M W, et al. Protective efficacy of a targeted anti-caries DNA plasmid against cariogenic bacteria infections. Vaccine, 2007, 25: 1191-1195.
13. Adar Y, Singer Y, Levi R, et al. A universal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine, 2009, 27: 2099-2107.
14. Bargieri D Y, Leite J A, Lopes S C, et al. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium. Vaccine, 2010, 28: 2818-2826.
15. Honko A N, Sriranganathan N, Lees C J, et al. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun, 2006, 74: 1113-1120.
16. McDonald W F, Huleatt J W, Foellmer H G, et al. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J Infect Dis, 2007, 195: 1607-1617.
17. Song L, Zhang Y, Yun N E, et al. Superior efficacy of a recombinant flagellin: H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin. Vaccine, 2009, 27: 5875-5884.
18. Taylor D N, Treanor J J, Strout C, et al. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2. HA1 SI). Vaccine, 2011, 29: 4897-4902.
19. Treanor J J, Taylor D N, Tussey L, et al. Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine, 2010, 28: 8268-8274.
20. Shi W, Li Y H, Liu F, et al. Flagellin enhances saliva IgA response and protection of anti-caries DNA vaccine. J Dent Res, 2012, 91: 249-254.
21. Sun Y, Shi W, Yang J Y, et al. Flagellin-PAc fusion protein is a high-efficacy anti-caries mucosal vaccine. J Dent Res, 2012, 91: 941-947.
22. Fejerskov O. Changing paradigms in concepts on dental caries: consequences for oral health care. Caries Res, 2004, 38: 182-191.
23. Scheie A A, Petersen F C. The biofilm concept: consequences for future prophylaxis of oral diseases? Crit Rev Oral Biol Med, 2004, 15: 4-12.
24. Featherstone J D. The continuum of dental caries-evidence for a dynamic disease process. J Dent Res, 2004, 83: C39-42.
25. Gambhir R S, Singh S, Singh G, et al. Vaccine against dental caries-an urgent need. J Vaccines Vaccin, 2012, 3: 136.
26. McGhee, Michalek S M, Webb J, et al. Effective immunity to dental caries: protection of gnotobiotic rats by local immunization with Streptococcus mutans. J Immunol, 1975, 114: 300-305.
27. Talbman M A, Smith D J. Effects of local immunization with Streptococcus mutans on induction of salivary immunoglobulin A antibody and experimental dental caries in rats. Infect Immun, 1974, 9: 1079-1091.
28. Koga T, Yamashita Y, Nakano Y, et al. Surface proteins of Streptococcus mutans. Dev Biol Stand, 1995, 85: 363-369.
29. Kuramitsu H K. Virulence factors of mutans streptococci: role of molecular genetics. Crit Rev Oral Biol Med, 1993, 4: 159-176.
30. Guo J H, Jia R, Fan M W, et al. Construction and immunogenic characterization of a fusion anti-caries DNA vaccine against PAc and glucosyltransferase I of Streptococcus mutans. J Dent Res, 2004, 83: 266-270.
31. Jenkinson H F, Lamont R J. Streptococcal adhesion and colonization. Crit Rev Oral Biol Med, 1997, 8: 175-200.
32. Sun J, Yang X, Xu Q A, et al. Protective efficacy of two new anti-caries DNA vaccines. Vaccine, 2009, 27: 7459-7466.
33. Smith D J. Dental caries vaccines: prospects and concerns. Crit Rev Oral Biol Med, 2002, 13: 335-349.
34. Smith D J, King W F, Rivero J, et al. Immunological and protective effects of diepitopic subunit dental caries vaccines. Infect Immun, 2005, 73: 2797-2804.
35. Wachsmann D, Klein J P, Scholler M, et al. Serum and salivary antibody responses in rats orally immunized with Streptococcus mutans carbohydrate protein conjugate associated with liposomes. Infect Immun, 1986, 52: 408-413.
36. Smith D J, Taubman M A, Ebersole J L. Effects of local immunization with glucosyltransferase fractions from Streptococcus mutans on dental caries in hamsters caused by homologous and heterologous serotypes of Streptococcus mutans. Infect Immun, 1978, 21: 843-851.
37. Li F, Michalek S M, Dasanayake A P, et al. Intranasal immunization of humans with Streptococcus mutans antigens. Oral Microbiol Immunol, 2003, 18: 271-277.
38. Smith D J, Taubman M A. Ontogeny of immunity to oral microbiota in humans. Crit Rev Oral Biol Med, 1992, 3: 109-133.
39. Smith D J, Taubman M A. Emergence of immune competence in saliva. Crit Rev Oral Biol Med, 1993, 4: 335-341.
40. Smith D J, Mattos-Graner R O. Secretory immunity following mutans streptococcal infection or immunization. Curr Top Microbiol Immunol, 2008, 319: 131-156.
41. Lehner T. Immunology of Oral Diseases. Oxford: Blackwell Scientific Publications, 1992.
42. Marcotte H, Lavoie M C. Oral microbial ecology and the role of salivary immunoglobulin A. Microbiol Mol Biol Rev, 1998, 62: 71-109.
43. Russell M W, Childers N K, Michalek S M, et al. A caries vaccine? The state of the science of immunization against dental caries. Caries Res, 2004, 38: 230-235.
44. Smith D J, Taubman M A. Oral immunization of humans with Streptococcus sobrinus glucosyltransferase. Infect Immun, 1987, 55: 2562-2569.
45. Smith D J, Taubman M A. Effect of local deposition of antigen on salivary immune responses and reaccumulation of mutans streptococci. J Clin Immunol, 1990, 10: 273-281.
46. Michalek S M, Childers N K. Development and outlook for a caries vaccine. Crit Rev Oral Biol Med, 1990, 1: 37-54.
47. Ogra P L M J, Lamm M E, Strober W, et al. Mucosal Immunology. San Diego: Academic Press, 1999.
48. Russell M W, Hajishengallis G, Childers N K, et al. Secretory immunity in defense against cariogenic mutans streptococci. Caries Res, 1999, 33: 4-15.
49. Borges O, Lebre F, Bento D, et al. Mucosal vaccines: recent progress in understanding the natural barriers. Pharm Res, 2010, 27: 211-223.
50. Kiyono H, Fukuyama S. NALT-versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol, 2004, 4: 699-710.
51. Fontana M, Dunipace A J, Stookey G K, et al. Intranasal immunization against dental caries with a Streptococcus mutans-enriched fimbrial preparation. Clin Diagn Lab Immunol, 1999, 6: 405-409.
52. Beutler B A. TLRs and innate immunity. Blood, 2009, 113: 1399-1407.
53. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol, 2004, 4: 499-511.
54. Coffman R L, Sher A, Seder R A. Vaccine adjuvants: putting innate immunity to work. Immunity, 2010, 33: 492-503.
55. Lightfield K L, Persson J, Brubaker S W, et al. Critical function for Naip5 in inflammasome activation by a conserved carboxy-terminal domain of flagellin. Nat Immunol, 2008, 9: 1171-1178.
56. Zhao Y, Yang J, Shi J, et al. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature, 2011, 477: 596-600.
57. Vijay-Kumar M, Carvalho F A, Aitken J D, et al. TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin. Eur J Immunol, 2010, 40: 3528-3534.
58. Mizel S B, Bates J T. Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol, 2010, 185: 5677-5682.
59. Hayashi F, Smith K D, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature, 2001, 410: 1099-1103.
60. Liu F, Yang J, Zhang Y, et al. Recombinant flagellins with partial deletions of the hypervariable domain lose antigenicity but not mucosal adjuvancy. Biochem Biophys Res Commun, 2010, 392: 582-587.
61. Huleatt J W, Jacobs A R, Tang J, et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine, 2007, 25: 763-775.
62. Katz J, Harmon C C, Buckner G P, et al. Protective salivary immunoglobulin A responses against Streptococcus mutans infection after intranasal immunization with S. mutans antigen I/II coupled to the B subunit of cholera toxin. Infect Immun, 1993, 61: 1964-1971.
63. Zhang P, Jespersgaard C, Lamberty-Mallory L, et al. Enhanced immunogenicity of a genetic chimeric protein consisting of two virulence antigens of Streptococcus mutans and protection against infection. Infect Immun, 2002, 70: 6779-6787.
64. Nempont C, Cayet D, Rumbo M, et al. Deletion of flagellin's hypervariable region abrogates antibody-mediated neutralization and systemic activation of TLR5-dependent immunity. J Immunol, 2008, 181: 2036-2043.
65. Yang J, Zhong M, Zhang Y, et al. Antigen replacement of domains D2 and D3 in flagellin promotes mucosal IgA production and attenuates flagellin-induced inflammatory response after intranasal immunization. Hum Vaccin Immunother, 2013, 9: 1-9.
66. ClinicalTrials. gov. Comparative safety and immunogenicity of 1. 0 μg intramuscular (i. m.) and 2. 0 μg subcutaneous (s. c.) dosing with VAX 102 (M2e-flagellin) universal influenza vaccine in healthy adults. 2009. http://www. clinicaltrials. gov/ct2/show/NCT00921947?term=influenza+and+universal& rank=2.
67. Lycke N. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol, 2012, 12: 592-605.
68. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine, 2007, 25: 5467-5484.
69. Czerkinsky C, Holmgren J. Enteric vaccines for the developing world: a challenge for mucosal immunology. Mucosal Immunol, 2009, 2: 284-287.
70. Holmgren J. Actions of cholera toxin and the prevention and treatment of cholera. Nature, 1981, 292: 413-417.
71. Plotkin S A. Correlates of protection induced by vaccination. Clin Vaccine Immunol, 2010, 17: 1055-1065.